Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane (Q47607706)

4 February 2018

title

Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane (English)

1 reference

4 February 2018

1 reference

0 references

2

Antonella Folgori

1 reference

4 February 2018

author name string

Alessandra Vitelli

1

1 reference

4 February 2018

Elisa Scarselli

3

1 reference

4 February 2018

Stefano Colloca

4

1 reference

4 February 2018

Stefania Capone

5

1 reference

4 February 2018

Alfredo Nicosia

6

1 reference

4 February 2018

publication date

19 October 2017

1 reference

4 February 2018

Expert Review of Vaccines

published in

1 reference

4 February 2018

volume

16

1 reference

4 February 2018

issue

12

1 reference

4 February 2018

page(s)

1241-1252

1 reference

4 February 2018

Toll-like receptors and innate antiviral responses

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Inflammasome control of viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Viral vectors as vaccine carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Adenoviruses as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Adenoviral vectors for gene transfer and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Complement activation by recombinant adenoviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Pitfalls in the identification of adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

The viruses of wild pigeon droppings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Creation of a panel of vectors based on ape adenovirus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Chimpanzee-origin adenovirus vectors as vaccine carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Immunomodulatory functions encoded by the E3 transcription unit of adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Enhanced Oncolytic Activities of the Telomerase-Specific Replication-Competent Adenovirus Expressing Short-Hairpin RNA against Dicer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Replication-defective vector based on a chimpanzee adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Host immune responses to chronic adenovirus infections in human and nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Protection of non-human primates against rabies with an adenovirus recombinant vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Adenovirus receptors: implications for tropism, treatment and targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Perspectives on mucosal vaccines: is mucosal tolerance a barrier?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Exploiting Mucosal Immunity for Antiviral Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Mucosal immunity and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Mucosal immunity and novel tuberculosis vaccine strategies: route of immunisation-determined T-cell homing to restricted lung mucosal compartments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doub

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Adenoviral Vector Vaccination Induces a Conserved Program of CD8(+) T Cell Memory Differentiation in Mouse and Man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Safety studies on an adenovirus recombinant vaccine for rabies (AdRG1.3-ONRAB) in target and non-target species

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Carbohydrate-based ice recrystallization inhibitors increase infectivity and thermostability of viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

Orchestrating immune check-point blockade for cancer immunotherapy in combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1394842

10.1080/14760584.2017.1394842

21 January 2018

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018